A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
Theodoros Karantanos(Johns Hopkins University), Suman Paul(Johns Hopkins University), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Brandy Perkins(Johns Hopkins University), Teodora Supeanu(Johns Hopkins University), Ivana Gojo(Johns Hopkins University), Bogdan C. Paun(Johns Hopkins University), Theodora Chatzilygeroudi(Johns Hopkins University), Linda Resar(Johns Hopkins University), Tushar D. Nichakawade(Howard Hughes Medical Institute), Gabriel Ghiaur(Johns Hopkins University), J. David Peske(Johns Hopkins University), Zanshé Thompson(University of South Carolina), Yoon‐Kyo An(Johns Hopkins University), Nour Sabiha Naji(Johns Hopkins University), Taha Ahmedna(Howard Hughes Medical Institute), Mark J. Levis(Sidney Kimmel Cancer Center), Styliani Karanika(Johns Hopkins University), Li Luo(Johns Hopkins University), Xinghan Zeng(Johns Hopkins University), Bum Seok Lee(Johns Hopkins University), Evangeline Watson(Howard Hughes Medical Institute), Melanie Klausner(Johns Hopkins University), Amy E. DeZern(Johns Hopkins University)
Cited by 0
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
|Oncogene|2013|879
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
|Nature|2015|501
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
|Cancer Chemotherapy and Pharmacology|1989|406